CDK9 and malignant colon neoplasm: HCT116 colon cancer cells were exposed for 6 h to different doses of toyocamycin (50–500 nM) and to another CDK9 inhibitor (BAY1251152, 1–10 μM, 16 h) as control (Figure 4C).